Drugs / IMCY-0098
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials · 1 met primary | ||||||
| Phase 1 | NCT04190693 | Feb → Oct 2019 | type 1 diabetes mellitus | Imcyse SA | Completed | No outcome recorded |
| Phase 1 | NCT03272269 | Aug 2017 → Apr 2019 | type 1 diabetes mellitus | Imcyse SA | Completed | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT04524949 | Dec 2020 → Jan 2024 | type 1 diabetes mellitus | Imcyse SA | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-01-13 | Imcyse SA | Results Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study imcyse.com ↗
Importantly, (3) in this initial analysis, Imotope™ treatment, when compared to the placebo, prevented the expansion of a population of antigen-specific CD4+ T cells with pathogenic signature. |
| 2019-09-18 | Imcyse SA | Results Imcyse to present first-in-human phase 1B study results in Type 1 diabetes at EASD 2019 imcyse.com ↗
Results of the clinical trial have shown an excellent safety profile, reaching the primary study objective. |
| 2019-08-27 | Imcyse SA | Results Imcyse reports successful first-in-human phase 1B study in type 1 diabetes with IMCY-0098 imcyse.com ↗
Results of the clinical trial have shown an excellent safety profile, reaching the primary study objective. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-03-01 | Imcyse SA | Imcyse Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY-0098 for Type 1 Diabetes imcyse.com ↗ |
| 2022-01-13 | Imcyse SA | Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study imcyse.com ↗ |
| 2019-09-18 | Imcyse SA | Imcyse to present first-in-human phase 1B study results in Type 1 diabetes at EASD 2019 imcyse.com ↗ |
| 2019-08-27 | Imcyse SA | Imcyse reports successful first-in-human phase 1B study in type 1 diabetes with IMCY-0098 imcyse.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMCY-0098 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03272269 ↗ |
| Action | Deplete | “promoting the specific elimination of pathogenic T cells” PMID 37226224 ↗ May 2023 |
| Modality | Peptide | “IMCY-0098 is a peptide derived from human proinsulin” PMID 37226224 ↗ May 2023 |
| Route | Subcutaneous | “450 μg subcutaneously” PMID 38902652 ↗ Jun 2024 |